1A. Piga,Paolo Giordani,Agata Quattrone,Marco Giulioni,Giorgio De Signoribus,Stefania Antognoli,Riccardo Cellerino. A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma[J] 1997,Cancer Immunology, Immunotherapy(6):348～351
4Spigel DR,Hainsworth JD,Sosman JA,et al.Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC):update of a phase Ⅱ multicenter trial (abstract)[J].J Clin Oncol,2005,23(Suppl):387(Abstr4540)
5Ahmad T,Eisen T.Kinase inhibition with BAY 43-9006 in renal cell carcinoma[J].Clin Cancer Res,2004,10 (18 Pt 2):6388S～6392S
6Eisen T,Bukoswki R,Staehler M,et al.Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma (RCC):impact of crossover on survival[J].J Clin Oncol 2006,24:223s (abstract 524)
7Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2006,24(1):16～24
8Rini B,George D,Michaelson M,et al.Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)[J].Proc Am Soc Clin Oncol,2006,24(18S):222s (abstr 4522)
9Rini B,Rixe O,Bukowski R,et al.AG-013736,a multi-target tyrosine kinase receptor inhibitor,demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory,metastatc renal cell cancer (RCC)[J].Proc Am Soc Clin Oncol,2005,23 (16s):380s (abstr 4509)
10George D,Michaelson D,Reitsma D,et al.Phase Ⅰ study of PTK787/ZK 222584(PTK/ZK) in metastatic renal cell carcinoma[J].Proc Am Soc Clin Oncol,2003,22:385(abstr 1548)
